SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Cipla to receive potential investment from FIL Capital for its WOS

21 Jul 2015 Evaluate

Cipla has received an approval to accept a potential investment by FIL Capital Investments (Mauritius) II, or any of its affiliate in a wholly owned subsidiary (WOS) of the company (proposed to be incorporated) to whom Cipla will be divesting its consumer healthcare business on a going-concern basis.

The board of directors at their meeting held on July 20, 2015 has approved for the same. The approval is subject to execution of binding agreements, and the transaction will be subject to relevant regulatory approvals.

Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 150 countries. Its portfolio includes over 1500 products across wide range of therapeutic categories with one quality standard globally.


Cipla Share Price

1233.60 -4.70 (-0.38%)
20-Apr-2026 09:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1673.75
Dr. Reddys Lab 1235.00
Cipla 1233.60
Zydus Lifesciences 937.25
Lupin 2328.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×